Vancouver, Canada, Sept. 01, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results